Pfizer: Pfizer to Discontinue Development Program for PF-07265803 for LMNA-Related Dilated…
Pfizer Inc. (NYSE: PFE) today announced that an interim futility analysis of the global Phase 3 trial, REALM-DCM, designed to evaluate the efficacy and safety of PF-07265803 in patients with symptomatic dilated cardiomyopathy (DCM) due to!-->…